Primary prevention of cardiovascular disease: New guidelines, technologies and therapies

Mark R. Nelson, Jennifer A. Doust

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

A trend in primary prevention of cardiovascular disease (CVD) has been a move away from managing isolated risk factors, such as hypertension and dyslipidaemia, towards assessment and management of absolute CVD risk. In Australian guidelines, absolute CVD risk is calculated as the probability of a stroke, transient ischaemic attack, myocardial infarction, angina, peripheral arterial disease or heart failure occurring within the next 5 years. Absolute CVD risk should be regularly assessed in patients aged 45 years or older (35 years or older in Aboriginal and Torres Strait Islander people) using the Australian absolute CVD risk calculator (http://www.cvdcheck.org.au). For patients currently taking a blood pressure (BP)-lowering or lipid-lowering agent, pretreatment values should be used to calculate risk. Patients at high absolute risk of CVD (>15% over 5 years) should be treated with both BP-lowering and lipidlowering agents, unless contraindicated or clinically inappropriate. For patients at moderate absolute risk of CVD (10%-15%) treatment with a BP-lowering and/or a lipid-lowering agent should be considered if the risk remains elevated after lifestyle interventions, BP is ≥160/100mmHg, there is a family history of premature CVD, or the patient is of South Asian, Middle Eastern, Maori, Pacific Islander, Aboriginal or Torres Strait Islander ethnicity. BP measurements taken using an oscillometric device can be used to approximate mean daytime ambulatory BP.

Original languageEnglish
Pages (from-to)606-610
Number of pages5
JournalMedical Journal of Australia
Volume198
Issue number11
DOIs
Publication statusPublished - 17 Jun 2013

Fingerprint

Primary Prevention
Cardiovascular Diseases
Guidelines
Technology
Blood Pressure
Therapeutics
Lipids
Peripheral Arterial Disease
Transient Ischemic Attack
Dyslipidemias
Life Style
Heart Failure
Stroke
Myocardial Infarction
Hypertension
Equipment and Supplies

Cite this

@article{d3a08b3e5828410abdb18e7c86833192,
title = "Primary prevention of cardiovascular disease: New guidelines, technologies and therapies",
abstract = "A trend in primary prevention of cardiovascular disease (CVD) has been a move away from managing isolated risk factors, such as hypertension and dyslipidaemia, towards assessment and management of absolute CVD risk. In Australian guidelines, absolute CVD risk is calculated as the probability of a stroke, transient ischaemic attack, myocardial infarction, angina, peripheral arterial disease or heart failure occurring within the next 5 years. Absolute CVD risk should be regularly assessed in patients aged 45 years or older (35 years or older in Aboriginal and Torres Strait Islander people) using the Australian absolute CVD risk calculator (http://www.cvdcheck.org.au). For patients currently taking a blood pressure (BP)-lowering or lipid-lowering agent, pretreatment values should be used to calculate risk. Patients at high absolute risk of CVD (>15{\%} over 5 years) should be treated with both BP-lowering and lipidlowering agents, unless contraindicated or clinically inappropriate. For patients at moderate absolute risk of CVD (10{\%}-15{\%}) treatment with a BP-lowering and/or a lipid-lowering agent should be considered if the risk remains elevated after lifestyle interventions, BP is ≥160/100mmHg, there is a family history of premature CVD, or the patient is of South Asian, Middle Eastern, Maori, Pacific Islander, Aboriginal or Torres Strait Islander ethnicity. BP measurements taken using an oscillometric device can be used to approximate mean daytime ambulatory BP.",
author = "Nelson, {Mark R.} and Doust, {Jennifer A.}",
year = "2013",
month = "6",
day = "17",
doi = "10.5694/mja12.11054",
language = "English",
volume = "198",
pages = "606--610",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AUSTRALASIAN MED PUBL CO LTD",
number = "11",

}

Primary prevention of cardiovascular disease: New guidelines, technologies and therapies. / Nelson, Mark R.; Doust, Jennifer A.

In: Medical Journal of Australia, Vol. 198, No. 11, 17.06.2013, p. 606-610.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Primary prevention of cardiovascular disease: New guidelines, technologies and therapies

AU - Nelson, Mark R.

AU - Doust, Jennifer A.

PY - 2013/6/17

Y1 - 2013/6/17

N2 - A trend in primary prevention of cardiovascular disease (CVD) has been a move away from managing isolated risk factors, such as hypertension and dyslipidaemia, towards assessment and management of absolute CVD risk. In Australian guidelines, absolute CVD risk is calculated as the probability of a stroke, transient ischaemic attack, myocardial infarction, angina, peripheral arterial disease or heart failure occurring within the next 5 years. Absolute CVD risk should be regularly assessed in patients aged 45 years or older (35 years or older in Aboriginal and Torres Strait Islander people) using the Australian absolute CVD risk calculator (http://www.cvdcheck.org.au). For patients currently taking a blood pressure (BP)-lowering or lipid-lowering agent, pretreatment values should be used to calculate risk. Patients at high absolute risk of CVD (>15% over 5 years) should be treated with both BP-lowering and lipidlowering agents, unless contraindicated or clinically inappropriate. For patients at moderate absolute risk of CVD (10%-15%) treatment with a BP-lowering and/or a lipid-lowering agent should be considered if the risk remains elevated after lifestyle interventions, BP is ≥160/100mmHg, there is a family history of premature CVD, or the patient is of South Asian, Middle Eastern, Maori, Pacific Islander, Aboriginal or Torres Strait Islander ethnicity. BP measurements taken using an oscillometric device can be used to approximate mean daytime ambulatory BP.

AB - A trend in primary prevention of cardiovascular disease (CVD) has been a move away from managing isolated risk factors, such as hypertension and dyslipidaemia, towards assessment and management of absolute CVD risk. In Australian guidelines, absolute CVD risk is calculated as the probability of a stroke, transient ischaemic attack, myocardial infarction, angina, peripheral arterial disease or heart failure occurring within the next 5 years. Absolute CVD risk should be regularly assessed in patients aged 45 years or older (35 years or older in Aboriginal and Torres Strait Islander people) using the Australian absolute CVD risk calculator (http://www.cvdcheck.org.au). For patients currently taking a blood pressure (BP)-lowering or lipid-lowering agent, pretreatment values should be used to calculate risk. Patients at high absolute risk of CVD (>15% over 5 years) should be treated with both BP-lowering and lipidlowering agents, unless contraindicated or clinically inappropriate. For patients at moderate absolute risk of CVD (10%-15%) treatment with a BP-lowering and/or a lipid-lowering agent should be considered if the risk remains elevated after lifestyle interventions, BP is ≥160/100mmHg, there is a family history of premature CVD, or the patient is of South Asian, Middle Eastern, Maori, Pacific Islander, Aboriginal or Torres Strait Islander ethnicity. BP measurements taken using an oscillometric device can be used to approximate mean daytime ambulatory BP.

UR - http://www.scopus.com/inward/record.url?scp=84879176807&partnerID=8YFLogxK

U2 - 10.5694/mja12.11054

DO - 10.5694/mja12.11054

M3 - Article

VL - 198

SP - 606

EP - 610

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 11

ER -